MSLN and Miyoshi myopathy: Fibulin-3 has recently been suggested as a new tumour biomarker for MM.13,26 Pass et al. presented that plasma fibulin-3 levels can distinguish an asbestos exposed healthy person from patients with MM.13 Creaney et al. recognized soluble mesothelin as a superior diagnostic biomarker for MM compared with fibulin-3, while fibulin-3 was indicated to provide superior prognostic information compared with mesothelin.26 However, to our knowledge and available literature, fibulin-3 has not been studied yet as a biomarker for evaluating tumour response to treatment.